This investment marks a strategic move to capture a greater share of the U.S. market, which accounts for 45% of the global night vision sector. With demand rising in both defence and commercial markets, Exosens aims to strengthen its foothold in the world’s largest market.
The increasing demand for night vision technology is being driven by rising defence budgets and the need for enhanced night-time operational capabilities. Recent conflicts and high-intensity combat scenarios have highlighted the importance of advanced night vision systems for military effectiveness.
Exosens’ subsidiary, Photonis, is a recognised leader in night vision technology, specialising in image intensifier tubes that enhance situational awareness and mobility in low-light conditions. These tubes are essential for soldiers’ tactical operations, improving targeting, driving, and agility in the field.
The new U.S. facility will begin production in early 2027, benefiting from existing synergies within the company’s Photonis Scientific Inc. subsidiary. By manufacturing “Made in America” image intensifier tubes, Exosens aims to meet growing domestic demand while strengthening its global presence.
Jérôme Cerisier, CEO of Exosens, stated that the expansion is a key step in the company’s strategy. He emphasised that the new production capacity will allow Exosens to deliver high-performance products in large volumes, tailored to U.S. market requirements.
As NATO and Tier-1 allies continue to increase their procurement of night vision systems, Exosens’ investment reflects the growing need for cutting-edge night vision solutions. With its expansion into the U.S., the company is well-positioned to play a leading role in the future of night vision technology.
